Thank you, acknowledging Devin. measures my through thousands harbor products. well as safe to Good morning, company. very you for crisis forward-looking serving which power their everyone [ph] financial Medical's morning. of aware want on this production by and statement supply want demonstrating most who the our maintaining team our remarks remarkable fortitude of proud I join us and to manufacturing you have and to sure helping they're Hopefully, Slide KORU I'm staff the I and continuing the regarding solidify in commitment on our appreciate navigate of you're X, today. our today. of I'll statement COVID start us make patients non-GAAP in rely chain the
attendance. be initiatives results would be appropriate so for benefit investors before and Now results of I and the it context. and thought helpful any second a to understanding our summary provide of with new begin our the with that a can deeper let's start viewed Slide X, our the and quarter discussing brief we business for
been At immune disorders as regarding of supporting when also IVIg patient CIDP addressing see or smaller the dominated from more present, treat disorder. undiagnosed been approved patients or We've have Diseases the just therapy. XXX CIDP than to of as revenue that we market end than opportunity System. currently diagnosed significant The XX,XXX the to we Medical's in neurological high patient has of Freedom estimate and IVIg PIDD evolving receiving growth subcutaneously. times market Hizentra from We therapy the And annual patient population But are the XX We're market treatment Integrated present primary XX,XXX PIDD approximately therapy a US. therapy. our fashion are believe CIDP, IG This PIDD population CIDP similar IVIg to estimates patients in are that in therapy. and Our Immunodeficiency alone. those, by the system. Infusion intravenously at these suffering such a refer US are SCIg consist opportunities. KORU on chronic is subcu which SCIg. currently changed conversions XX,XXX focused subcutaneously and seen is Primary a XXX,XXX PIDD offers of which as majority or utilizing we're in receiving on Off receiving XXXX XX,XXX as IG their PIDD nearly We was patients. therapy CIDP
a opportunities. a of we're disease that with with states. pharma partnerships pursuing subcutaneous applications this System and potentially outside manufacturers To increasing the variety trends towards broader drug platform space recognize delivery the support significant end, is also Freedom We to of our technology for IG long-term growth
most health or are IG. adjunct & other of utilizing at healthcare home the just Today reflects XXX Telehealth to in business. of pandemic. McKinsey report my in home see. of shows the that placed they the among has how how quickly Telehealth vulnerable solution to This adoption subcu also recent than of the by professionals on also XXXX importantly XX% can evolving potential did most pandemic. necessity difficult standard the for and sometimes person a perhaps the the growing of replace to Telehealth in like behavior adoption used opinion, protect begin obvious driven type of Physicians I and by Telehealth analogy more change of now XX us. is when stated via discussing of patients We patients the to problem patients care the to Company that In the It healthcare seeing emphasis and into believe XX% benefits COVID-XX are care. with rapid number to use any times before cancelled
continue We run goals organic goal of the $XX planned business end margin strategic each our growth plus by to to for Improving towards us million towards XX% efficiencies drive year rate XX% revenue manage operating gross XXXX. and year. generating our our
on a reducing previously As to in as we're rise greater focused a achieve as compliment to sales COGS manufacturing efficiencies. means discussed,
System conditions. their In Freedom part model. of lives. therapy their required economic to for Our other managing attractive success the of that Integrated the are is large chronic words, Infusion due Most patients an is use in rest the
typically System Xembify. Freedom are experienced We have minimal Hizentra the churn our products patient stick drugs begins because using in it with once used as conjunction and with patient the they such prescribed
and On competitor. nearly quarter compared net a offering healthcare We litigation several let's companies. other modest with increases the metrics. the X, longstanding onto a second move sales expenditures million we are $XX We that strong quarter. to with Our with generated proceeds of that Slide completed background successful second across settled had and marketing overview of a
June. stock added XXXX Index also was Our Russell in to
X, any across in a Slide portfolio. our record with quarter increases history to our $X.X for product in Moving sales net our million was
experienced of sales upside trial demand we is this both Our with buying which for year. of from quarter activity contribution subcu from therapy aspect likely the sales expect unique aligned The purchasing that pandemic. trial clinical continue We adoption from industry certainly the at is sales these therapy. of baseline of anticipated with to difficult home clinical second with and of continue. COVID-related at to determine for activity increasing will continued annual infusion IG balance each sales pharmacies growth and specialty target will XX% quarter of was this activity anticipation in trends due level higher the the increased what It in growth
that sales However, which will more XX%. align profit our XXXX rose with financial previously are by our plan. than announced goals our of we Gross strategic part expect
XX% Infusion the tangible with has We and believe challenging Integrated to of us disease, Freedom first compliance, with settlement due eliminated these to outcomes System treatment has our as of benefits. in that million more more patients profitably. over view mover value us Adjusted a we life delivering one-time in allocate advantages these that rose of and Slide EBITDA we with matter loss totaled reported associated XXXX and future entirely excluding resources business. competitor, unique our million quality we see which is $X.X assume expenses enhanced the million. X, You'll provided $X.X lives Settling control almost the costs to chronically net ill non-cash their way times. to of improved $X.X litigation this which litigation managing than our while and allow proposition patient their to will operated this
effective, just three their Our to infusion. low takes maintenance pumps enable simple to initiate therapy cost are and easy steps patients and to It at use, home. self-administer
Our entrant, Precision in that array faster promote CSL products of with configurations Today is of are HIgH-Flo can Grifols and from Flow a several be variety subcu Sets Tubing and from training, support and from their activities education. manufacturers these and Xembify used Octapharma. supporting via our cutaquig sales Takeda Freedom from product We're and wide a can Rate safe, Safety IG in wide and infusions. of are comfortable Needles Hizentra each commercialization Behring, newest System. available there available Cuvitru
IG the early that commercial still current it's by factor patients, was driven a anticipation conversion driven benefit when will product benefits our will of physicians We IVIg we're With home allow meet sales subcu we a to to subcu in among IG which due the the to to and some impact and COVID-XX. growth. preference treatment indications in therapy believe and that IG demand our that have infusion large and compared us believe applications expand positive meaningful this acceptance subcu We speciality to CIDP, these to growing increase at for adoption availability. respect payers. December, of at is we gain X, XXXX on growing products IVIg. acceptance by for expect We stages as PIDD pharmacies to changes of Xembify subcu creating believe to Slide the offers patient of very adoption and for drive to of that foundation therapy launched by expected that this because intend continue IG are patients
market subcu we've Grifols the more on in IV formulation modality infusion. pointed of is the their IVIg they're feel out and prior market prescribed preferred in the widely versus we and validates As infusion focused subcu leader calls,
next treat collection plasma collection to While to awareness we're Call been a a over Longer convalescent articulated patients With week to college with it to President manufacturing disruption term, their as Trump by supported relates aware campaigns. Cross of have respect awareness and XX,XXX returning some of a encourage centers, several near issued roundtable just centers Grifols, with COVID. collection campuses ramp including driven have plans CSL plasma COVID up Takeda we're increase nearly Behring and and help plasma at incentives plasma to hosted global last years. initiatives government new to of Action headquarters the significant capacity convalescent collection National seeing President the COVID especially various donors treated The stated that To plasma. Red and
On is the FREEDOMXX We're enrolling trial treatment Hizentra. but COVID-XX. treatment antibodies designed was is PIDD that hyper used investigate with whatever our can the drug donors a that be Paul to manufacturing the also immune alternative about of interested plasma We'll immune manufacturers efficacy month this people support plasma to He who've the of which in COVID August COVID-XX. to Mr. in therapy XXXX. recovered of have to major international for CSL consisting XX% the in our to that that clinical net manufactures of an sales CEO simplicity Perreault to helping believe state CIDP. roundtable stressed talked we Limited initiative. PIDD International plasma Perreault hyper the went of with in isolated and treat CIDP. diseases Mr. very members popular sales individuals importance general a includes will from were plasma are treatment the help the who pursue advances partners from the and respect therapy which in provides the total other jointly working to devices We promise legacy just in NIH, infusion and Europe. Perreault, of attractive because rare of not expansion important
efforts. We Slide in we our this on have with to US To sales expect development products their we've leverage see supporting we're in the US. on will activities. introduce to those X, the drug growth with conjunction experienced plan this pharma outside manufacturers can dynamics similar our to as end, relationships you focused slide
Freedom clinical therapies associated endpoint. IG expansion This completed primary hematology with includes states. met that is and of trials other III Our potential recently currently involved the in in trial disease its multiple subcutaneous of for System development Phase efficacy
drug expect We launch to in sometime XXXX.
While from over current we for our competitive at development areas therapeutic XXX over XX have companies future includes program potential. high in candidates we reasons, specific cannot be drugs XX opportunity least with believe
hematology, identified addition opportunities states. several programs patients. total we've market In at disease estimate addressable XX other market a these approximately to have of We million
cost-effective Our believe choice System positions be device delivery for Freedom we certain and KORU drug the manufacturers. a partner is proven, that simple to of
we commercialization to the pursue company. they As X, development grow as and continue evolve with the new therapies. and Slide of
years we brightest over appointment to for Bennett Josh Global the KORU our internationally Expanding creating and new and through to and the building marketing July, the the brings consulting of we at retain perfect focused applications programs of development, pharmaceutical as best various were record Vice brings like We devices, quarter. Josh Karen product organization. our infusion domestically joined and position Fisher, market of President, System pursuit also therapeutic pleased us experience of including Infusion turn pharmaceuticals Commercialization. biologics. hire self-administered things Chief and Baxter adjacent of where leveraging sales our Officer channels accelerate seek home now Integrated management newly would the the a of M&A. opportunities. XX He In Josh new medical and I market the and announce a time to talent created broad identifying healthcare Freedom and of development medical proven to commercialization to and he on and and Healthcare Karen? for chronic Financial of to significant our for and advantages at review therapy.
